Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Manufacturer has indicated some supply will be available in December, though there will be constraints because of backorders ...

KIMBERLY-CLARK is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54 ...

Kimberly-Clark shares declined marginally in the premarket session on Tuesday, after a sharp drop the previous day. ・The ...

The transaction, structured as a mix of cash and stock, represents an equity value of about USD 40 billion, excluding debt.

Kimberly-Clark (NASDAQ:KMB) is making a massive bet but investors aren't sure on how to feel about it. The maker of Kleenex ...

Evercore also said Kimberly’s move expands its footprint into two stable, cash-generative global categories, personal hygiene and consumer health, that have high barriers to entry and rational pricing ...